Delving into the Latest Updates on NUV-001 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Nuvamid SA

Active Organization

Nuvamid SA

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is a pilot study of daily dosing of NUV001 as a dietary supplement in 12 sickle cell disease patients with 3 months of follow-up plus 1 month after supplementation.The present study is designed to evaluate, first, the safety and tolerability parameters as well as to measure the plasma and urinary residues of daily oral doses of NUV001. Secondly, the study will evaluate the impact of NUV001 on biological parameters and quality of life of patients.

Start Date01 Apr 2023

Sponsor / Collaborator

LGD Holdings Ltd.

[+2]

CTRI/2022/08/044979

/ RecruitingNot ApplicableIIT

A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate Safety and Efficacy of Orally administered NUV001 nutraceutical supplement in Sickle Cell Disease (SCD) patients.

Start Date15 Sep 2022

Sponsor / Collaborator-

100 Clinical Results associated with NUV-001

Login to view more data

100 Translational Medicine associated with NUV-001

Login to view more data

100 Patents (Medical) associated with NUV-001

Login to view more data

100 Deals associated with NUV-001

Login to view more data